CBER Compliance Update FDLI Enforcement, Litigation and Compliance Conference December 8, 2014 Mary...
-
Upload
edwin-franklin -
Category
Documents
-
view
219 -
download
0
Transcript of CBER Compliance Update FDLI Enforcement, Litigation and Compliance Conference December 8, 2014 Mary...
CBER Compliance Update
FDLI Enforcement, Litigation and Compliance Conference December 8, 2014Mary Malarkey, DirectorOffice of Compliance and Biologics QualityCenter for Biologics Evaluation and Research
Office of Compliance and Biologics Quality
2
OCBQ’s mission is to ensure the quality of products regulated by CBER over their entire
lifecycle through pre-market review and inspection, and post-market review, surveillance,
inspection, outreach and compliance
3
Current OCBQ Priorities
• Continued FDASIA and DQSA Implementation – 2nd anniversary of enactment of FDASIA (July 9, 2014)
– FDASIA • PDUFA V – focus on “lessons learned”• Titles VII Drug Supply Chain and Title X Drug Shortages
– DQSA• DSCSA illegitimate and suspect product notification provision
• Engaged with CDER on Quality Metrics
4
DSCSA
• Beginning on January 1, 2015, a trading partner who determines that a product in its possession or control is an illegitimate product must notify the Food and Drug Administration (FDA or Agency) and certain immediate trading partners under section 582 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 360eee), as added by the Drug Supply Chain Security Act (DSCSA).
• Trading partner - manufacturers, repackagers, wholesale distributors, or dispensers
Current OCBQ Priorities - 2• Program Alignment
– Working with other agency components to address Dr. Hamburg’s decisions for implementation, communicated by memorandum on February 3, 2014.
• Other quality initiatives– Working with other agency components to update quality
guidance and implement standards for quality (e.g., Council on Pharmaceutical Quality)
• Preparedness activities– Centers for Innovation and Advanced Development in
Manufacturing – Ebola
• International – Mutual Reliance Initiative
Current OCBQ Priorities - 3• OCBQ Move to the White Oak Campus.
– OCBQ moved May 16 – August 25, 2014 – lot release laboratories relocated last.
– Pause for lot release sample submission until September 2, 2014; no effect on lot release protocols or release of products
• What’s next?– Increasing filling and lyophilization capacity for
production of reagents and standards for the other Essential Regulatory Laboratories, manufacturers and other global partners.
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/ucm345223.htm
7
White Oak Campus Map
8
United States v. Regenerative Sciences, LLC and Christopher Centeno, et al.
• The complaint for the injunction was filed August 6, 2010, by the Justice Department on behalf of the FDA in the U.S. District Court for the District of Columbia, against Regenerative Sciences and three of its employees, Christopher J. Centeno, M.D., John R. Schultz, M.D., and Michelle R. Cheever. The injunction the government requested would permanently prevent the company and cited individuals from adulterating and misbranding the cultured cell product (or any other drug) while the product, or one or more of its components, is held for sale after shipment in interstate commerce.
• Regenerative Sciences agreed to cease production of the cultured cell product while the case is pending.
9
US vs Regenerative Sciences LLC - 2
• On July 23, 2012, United States District Judge Rosemary Collyer granted summary judgment for the government and issued a permanent injunction prohibiting the defendants, from distributing adulterated or misbranded drugs or causing them to become adulterated or misbranded after shipment of one or more of their components in interstate commerce.
• The product at issue is an autologous cultured cell product that was subject to more than minimal manipulation during manufacturing and that was promoted as a treatment for a variety of orthopedic conditions. The court held that this product is a “drug” under the Federal Food, Drug, and Cosmetic Act and rejected the defendants' argument that it falls within the "practice of medicine" and thus outside the scope of the Act.
10
US vs Regenerative Sciences LLC -3
• The court also held that the Act's interstate commerce requirement was satisfied because its components were shipped in interstate commerce. The court also dismissed the eight counterclaims filed by the defendants, which challenged, under various theories, FDA's authority to regulate the autologous cell products and FDA's regulations for human cellular and tissue based products.
• Regenerative appealed the decision and on February 4, 2014, the DC Federal Circuit Court of Appeals ruled in the Agency’s favor
11
Vision for CBERCBER uses sound science and regulatory
expertise to: Protect and improve public and individual
health in the US and, where feasible, globally Facilitate development, approval of and access
to safe and effective products and promising new technologies
Strengthen CBER as a preeminent regulatory organization for biologics
INNOVATIVE TECHNOLOGY ADVANCING PUBLIC HEALTH
12
Public Access to CBER
CBER website:http://www.fda.gov/BiologicsBloodVaccines/default.htm
Phone: 1-800-835-4709 or 301-827-1800
Consumer Affairs Branch (CAB) Email: [email protected]
Phone: 301-827-3821
Manufacturers Assistance and Technical Training Branch (MATTB)
Email: [email protected]: 301-827-4081
Follow us on Twitter https://www.twitter.com/fdacber
13
Compliance Central with Compliance Central with FDA Center Compliance FDA Center Compliance
Directors (Part II)Directors (Part II)
Steve Silverman, DirectorSteve Silverman, Director
CDRH Office of ComplianceCDRH Office of Compliance
December 8, 2014December 8, 2014
The Office of Compliance has The Office of Compliance has reorganized.reorganized.
From:From:
The Office of Compliance has The Office of Compliance has reorganized.reorganized.
To:To:
17
The Case for Quality The Case for Quality • Support and ownership of quality go beyond Support and ownership of quality go beyond
quality/compliance unitsquality/compliance units
• A culture of quality yields benefits.A culture of quality yields benefits.
• Recent trends highlight the importance of quality.Recent trends highlight the importance of quality.
• ““Understanding Barriers to Medical Device Quality”Understanding Barriers to Medical Device Quality” http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDRH/CDRHReports/UCM277323.pdf
• October 31, 2011 webcast:October 31, 2011 webcast: http://fda.yorkcast.com/webcast/Viewer/?peid=7134123bd5c94d909fdae41fce3469411d
http://fda.yorkcast.com/webcast/Viewer/?peid=7134123bd5c94d909fdae41fce3469411d
18
The Case for Quality The Case for Quality Implementation PlanImplementation Plan
Initiative 1: Focus on QualityInitiative 1: Focus on Quality
Initiative 2: Enhanced TransparencyInitiative 2: Enhanced Transparency
Initiative 3: Stakeholder EngagementInitiative 3: Stakeholder Engagement
19
2013-2014 Case for Quality Activities2013-2014 Case for Quality Activities
Engage industry and other stakeholders in national venues
Engage industry and FDA districts in local venues
Partner with industry and other stakeholders to develop collaborative forums and
trustful engagements
Stakeholder Stakeholder
EngagementEngagement
Data TransparencyData TransparencyProvide relevant device quality data
Gather and assess stakeholder data needs
Develop a framework for delivering releasable information
Activities Sub-Initiative
Focus on QualityFocus on QualityDevelop, implement, and assess a pilot that changes engagement during an
inspection
Assess internal/external incentives and measures
Benchmark with other quality performance models
Case for Quality:Case for Quality:Implantable Device PilotImplantable Device Pilot
•Implantable battery-containing devicesImplantable battery-containing devices•Inspections focused on factors that Inspections focused on factors that affect device qualityaffect device quality•Prioritized Form FDA-483sPrioritized Form FDA-483s•Does the pilot improve quality and Does the pilot improve quality and resource allocation?resource allocation?
Spin Off
Update Program
Successful pilots can be Successful pilots can be
expanded.expanded.
Case for Quality: Case for Quality: Maturity ModelMaturity Model
FDLI’s Enforcement, Compliance, and Litigation Conference
Center for Tobacco ProductsOffice of Compliance and Enforcement
2014 Update
Ann Simoneau, Director
CTP Office of Compliance and Enforcement
December 8, 2014
24
Compliance and Enforcement Report
• Office of Compliance and Enforcement (OCE) created a comprehensive report covering 2009 through September 30, 2013
• Report includes several charts and graphs representing the advisory (WL) and enforcement activities of the office
• Report available on the CTP website
• Plan to update periodically
Regulations and GuidancesFinal Rule Tobacco Products, User Fees, Requirements for the Submission of Data Needed to Calculate User Fees
for Domestic Manufacturers and Importers of Tobacco Products07/10/14
Proposed Rule
Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act
04/25/14
Proposed Rule
National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions
01/23/14
Guidance Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007
09/29/14
Guidance Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products
07/16/14
Draft Guidance
Substantial Equivalence Reports: Manufacturer Requests for Extensions or to Change the Predicate Tobacco Product
07/15/14
Guidance Civil Money Penalties for Tobacco Retailers - Responses to Frequently Asked Questions 06/26/14
Guidance Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments
04/07/14
Draft Guidance
Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent
02/25/14
Deeming (Proposed Rule)
On April 24, 2014, FDA proposed a new rule that would extend CTP’s authority to cover additional tobacco products.Products that would be “deemed” to be subject to FDA regulation are those that meet the statutory definition of a tobacco product, including:•Electronic Cigarettes (e‐cigarettes)•Cigars•Pipe Tobacco•Nicotine Gels•Waterpipe (Hookah)•Tobacco Dissolvables not already under the FDA’s authority
Retailer Enforcement
FY 14 Results• Contracts with 55 jurisdictions• Contracts with tribes• Over 124,000 inspections completed• Over 8,100 Warning Letters• Over 1,070 CMP’s issued• Sale to minor violation rate for FY 14 was 11.4%
Internet Surveillance
Issued WLs to online retailers– Sale of tobacco products to minors
• Minors were able to purchase regulated tobacco products from their websites
– Modified risk tobacco product violations– Flavored cigarette violations– Smokeless tobacco product warning
statement violations
“Provisional” Tobacco Products Found Not Substantially Equivalent (NSE)
• Misbranded and adulterated NSE tobacco products webpage
• Letters to regulated industry
• Draft Guidance – Enforcement Policy for Retailers
• Ongoing surveillance and inspections
• Notifications to retailers
User Fees
• Domestic manufacturers and importers of regulated tobacco products
• Currently applies to cigarettes, snuff, chewing tobacco, and roll-your-own tobacco
• Warning Letter for failure to pay user fees – King Mountain Tobacco Company, Inc.
• Import Alert – Lit Distributor, Inc. & DK Distributors, Inc.
Compliance WebinarsTitle DateOther Media Notifications 9/23/2014Draft Guidance – Substantial Equivalence Reports: Manufacturer Requests for Extensions or to Change the Predicate Tobacco Product
8/6/2014
FDA’s Proposed Regulation – “Deeming Tobacco Products To Be Subject to the Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Regulations on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products”
5/29/2014
Electronic Establishment Registration and Product Listing 4/7/2014Guidance for Industry on Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents
12/9/13